Geode Capital Management LLC Has $6.43 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

Geode Capital Management LLC increased its position in Sutro Biopharma, Inc. (NASDAQ:STRO) by 7.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,856,956 shares of the company’s stock after acquiring an additional 132,015 shares during the quarter. Geode Capital Management LLC owned about 2.27% of Sutro Biopharma worth $6,426,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Sutro Biopharma by 385.3% during the 3rd quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after purchasing an additional 216,757 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Sutro Biopharma by 222.0% during the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock worth $361,000 after buying an additional 71,844 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Sutro Biopharma by 30.7% in the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after acquiring an additional 25,416 shares during the period. State Street Corp grew its stake in shares of Sutro Biopharma by 5.2% in the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after acquiring an additional 81,855 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Sutro Biopharma by 1,195.1% during the third quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock worth $286,000 after acquiring an additional 76,152 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

Shares of NASDAQ STRO opened at $1.95 on Friday. The business has a fifty day moving average of $2.75 and a two-hundred day moving average of $3.41. Sutro Biopharma, Inc. has a 52-week low of $1.70 and a 52-week high of $6.13. The stock has a market cap of $160.80 million, a PE ratio of -1.21 and a beta of 1.09.

Analyst Ratings Changes

STRO has been the topic of several research analyst reports. Wells Fargo & Company decreased their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $11.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a report on Monday, November 18th. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a report on Tuesday, December 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Sutro Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $11.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.